Clarity Pharmaceuticals Ltd (CU6) — Cash Flow-to-Debt Ratio
Clarity Pharmaceuticals Ltd (CU6) has a Cash Flow-to-Debt Ratio of -2.09x as of December 2025, meaning its operating cash flow of AU$-47.79 Million could theoretically repay -2% of its total liabilities (AU$22.86 Million) in one year. See working capital position of Clarity Pharmaceuticals Ltd to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Clarity Pharmaceuticals Ltd Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Clarity Pharmaceuticals Ltd across 8 annual periods. Also explore CU6 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Clarity Pharmaceuticals Ltd (2018–2025)
Year-by-year debt coverage analysis for Clarity Pharmaceuticals Ltd. For market capitalisation and broader financial context, see Clarity Pharmaceuticals Ltd (CU6) total market value.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.01x | AU$-54.77 Million | AU$10.94 Million | ▲ +3.5% |
| 2024 | -5.19x | AU$-43.24 Million | AU$8.33 Million | ▼ -45.7% |
| 2023 | -3.56x | AU$-27.50 Million | AU$7.72 Million | ▼ -102.9% |
| 2022 | -1.76x | AU$-13.31 Million | AU$7.59 Million | ▲ +46.6% |
| 2021 | -3.29x | AU$-7.68 Million | AU$2.34 Million | ▲ +54.0% |
| 2020 | -7.14x | AU$-6.83 Million | AU$956.09K | ▼ -119.0% |
| 2019 | -3.26x | AU$-3.71 Million | AU$1.14 Million | ▼ -86.5% |
| 2018 | -1.75x | AU$-1.50 Million | AU$857.04K | — |